LONE TREE, COLORADO — Cochlear announced that its Nucleus® Nexa® System is now available to eligible U.S. military veterans receiving care through Department of Veterans Affairs (VA) clinics nationwide.
The availability of the Nucleus Nexa System provides veterans with hearing loss access to Cochlear’s newest cochlear implant technology, which the company describes as designed to support more connected and adaptable hearing experiences.
The Nucleus Nexa System is described by Cochlear as the world’s first smart cochlear implant system.1,* The system includes upgradeable firmware and internal memory and, when paired with the Power Compact rechargeable battery, is offered as the smallest and lightest sound processor with all-day battery life currently available, according to the company.2,3,#
When used with the Nucleus 8 Nexa or Kanso® 3 Nexa sound processors, the system is designed to automatically adjust performance in response to changing listening environments.
“Veterans have given so much in service to our country, and we are excited to provide them access to the very best hearing technology available. Our mission is to help people hear and be heard, and this expansion of access to the new Nucleus Nexa System reflects our commitment to those who have served.”
–Lisa Aubert, President of Cochlear North America
According to published data, hearing loss is the most common service-connected disability among U.S. military veterans, with estimates indicating that three in five veterans are affected.4,5
Veterans seeking additional information about eligibility and access to Cochlear hearing solutions through the VA system are encouraged to visit cochlear.com.
About Cochlear Limited (ASX: COH)
Cochlear was founded following Professor Graeme Clark’s development of the first multi-channel cochlear implant, inspired by his father’s experience with hearing loss. Since 1981, the company reports it has helped more than 750,000 people of all ages in over 180 countries access implantable hearing solutions.
Cochlear employs more than 5,500 people globally and reports investing more than AUD $3 billion in research and development to date. The company focuses on advancing implantable hearing technologies to address the needs of people living with hearing loss worldwide.
References
1 Cochlear Limited. FUN5261. FDA Approval Letter for CI1000 Series Implant System. 2024.
2 Cochlear Limited. D1190805. Processor Size Comparison. 2023.
3 Cochlear Limited. D2127964. Nucleus 8 Sound Processor Battery Estimations with CI1000 Implant. 2023.
4 Hearing Health Foundation. Hearing Loss & Tinnitus Statistics [Internet]. 2016 [cited 23 February 2016]. Available from: http://hearinghealthfoundation.org/statistics.
5 Hearing Health Foundation. A Salute to the Veterans [Internet]. 2016 [cited 23 February 2016]. Available from: http://hearinghealthfoundation.org/salute_to_the_veterans.
*The only cochlear implant having onboard memory with upgradeable firmware. As future advancements or technology become available for the CI1000 series implant, a firmware update may be required in order to take advantage of newer features.
# Battery life varies for every user, according to the age of the battery, the programs used each day, implant type, skin thickness over the implant, and battery size and type. Streaming from compatible devices may reduce battery life. All-day hearing is defined as 16 hours. This feature is only compatible with CI1000 implants.
Please seek advice from a qualified health professional regarding treatment for hearing loss. Outcomes may vary. Always read the instructions for use. Not all products are available in all countries. Consult your health professional to determine whether Cochlear technology is appropriate for you.
